{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Celldex Therapeutics, Inc.
Celldex Therapeutics Hits Day High with Strong 7.72% Intraday Surge
Celldex Therapeutics, Inc. experienced a significant stock price increase today, reaching an intraday high. Despite this uptick, the company has faced challenges, including a substantial decline in net sales and negative operating cash flow. Overall, its performance metrics indicate mixed results amid ongoing sector volatility.
Celldex Therapeutics Stock Soars 7.5%, Hits Intraday High of $24.77
Celldex Therapeutics, Inc. experienced a notable increase in stock price on November 11, 2025, contrasting with the S&P 500's modest gain. However, the company has struggled with a significant decline in net sales and negative operating cash flow, reflecting ongoing profitability challenges and underperformance over the past year.
Celldex Therapeutics Hits Day Low of $24.40 Amid Price Pressure
Celldex Therapeutics, Inc. has faced significant stock price declines, with a notable drop today. The company reported a substantial decrease in net sales and negative operating cash flow, alongside a low debtors turnover ratio and negative return on equity, indicating ongoing financial challenges amid broader market gains.
Celldex Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators
Celldex Therapeutics, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $26.72. The company has experienced significant volatility over the past year. Technical indicators present a mixed outlook, while its performance has varied compared to the S&P 500 over different time frames.
Celldex Therapeutics Experiences Revision in Stock Evaluation Amid Market Dynamics
Celldex Therapeutics, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $26.83. The company has shown significant volatility over the past year, with a 52-week high of $29.38 and a low of $14.40, reflecting mixed performance indicators and varying returns compared to the S&P 500.
Celldex Therapeutics Experiences Evaluation Revision Amidst Market Dynamics and Performance Fluctuations
Celldex Therapeutics, Inc. has recently revised its evaluation amid market dynamics, with its stock priced at $26.38. The company has experienced significant volatility over the past year, with a 52-week high of $31.66 and a low of $14.40, reflecting varied performance compared to the S&P 500.
Is Celldex Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Celldex Therapeutics, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed monthly signals, and has outperformed the S&P 500 in the past month but underperformed over the past year.
Is Celldex Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Celldex Therapeutics, Inc. shows a bullish technical trend supported by positive MACD and RSI signals, despite some caution from mixed indicators like Bollinger Bands and KST, while outperforming the S&P 500 over the past month.
Is Celldex Therapeutics, Inc. technically bullish or bearish?
As of October 3, 2025, Celldex Therapeutics, Inc. shows a bullish technical trend with positive momentum indicators, although caution is advised due to mixed signals in longer timeframes.
Is Celldex Therapeutics, Inc. technically bullish or bearish?
As of August 27, 2025, Celldex Therapeutics, Inc. shows a mildly bullish trend based on weekly indicators, despite longer-term underperformance compared to the S&P 500.
Is Celldex Therapeutics, Inc. overvalued or undervalued?
As of November 9, 2022, Celldex Therapeutics, Inc. is considered risky and overvalued due to negative financial ratios and a poor long-term stock performance, despite recent short-term gains.
Is Celldex Therapeutics, Inc. overvalued or undervalued?
As of November 9, 2022, Celldex Therapeutics, Inc. is considered risky and overvalued due to troubling financial ratios, including a Price to Book Value of 2.02, an EV to EBITDA of -3.51, and a Return on Capital Employed of -584.07%, while its stock performance has significantly lagged behind the S&P 500 with a year-to-date return of -19.31%.
Is Celldex Therapeutics, Inc. technically bullish or bearish?
As of May 29, 2025, Celldex Therapeutics, Inc. shows a mildly bearish trend due to daily moving averages indicating bearishness, while weekly indicators suggest mild bullishness, but overall caution is advised due to mixed signals and lack of strong bullish momentum.
Who are in the management team of Celldex Therapeutics, Inc.?
As of March 2022, the management team of Celldex Therapeutics, Inc. includes Independent Chairman Ms. Karen Shoos, President and CEO Mr. Anthony Marucci, and Independent Directors Mr. Keith Brownlie, Mr. Herbert Conrad, Mr. James Marino, and Dr. Harry Penner. They are responsible for guiding the company's strategic decisions.
What does Celldex Therapeutics, Inc. do?
Celldex Therapeutics, Inc. is a biopharmaceutical company specializing in immunotherapy for cancer and other diseases, with a market cap of approximately $1.33 billion. As of March 2025, it reported net sales of $1 million and a net loss of $54 million.
How big is Celldex Therapeutics, Inc.?
As of Jun 18, Celldex Therapeutics, Inc. has a market capitalization of $1.33 billion, with net sales of $7.56 million and a net profit of -$178.85 million over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
